Lipids

, Volume 48, Issue 1, pp 51–61

High Serum Apolipoprotein E Determines Hypertriglyceridemic Dyslipidemias, Coronary Disease and ApoA-I Dysfunctionality

  • Altan Onat
  • Günay Can
  • Ender Örnek
  • Erkan Ayhan
  • Nihan Erginel-Ünaltuna
  • Sani N. Murat
Original Article
  • 368 Downloads

Abstract

The relevance of serum apolipoprotein E (apoE) levels to two hypertriglyceridemic dyslipidemias has not been clarified. We explored, in a cross-sectional (and short-term prospective) evaluation, the independent relationship of serum apoE to the atherogenic dyslipidemia, hypertriglyceridemia with elevated apoB (HtgB) and to apoA-I dysfunctionality, previously shown in Turkish adults to be independent of apoE genotype. Serum apoE concentrations were measured by immunonephelometry in 1,127 middle-aged adults. In multivariable regression analysis, apoE concentrations showed log-linear associations with apoB and apoA-I levels, waist circumference, independent of C-reactive protein (CRP), homeostatic model assessment (HOMA) index and other confounders. The likelihood of atherogenic dyslipidemia and of HtgB roughly tripled per 1-SD increment in apoE concentrations, additively to apoE genotype, HOMA, apoA-I, CRP concentrations and waist circumference; yet apoA-I, protective against atherogenic dyslipidemia, appeared to promote HtgB, a finding consistent with apoA-I dysfunctionality in this setting. Each 1-SD increment in the apoE level was moreover, associated in both genders with MetS (at OR 1.5), after adjustment for sex, age, apoB, apoA-I and CRP, or for apoE genotypes. Circulating apoE predicted in both genders age-adjusted prevalent and incident coronary heart disease (CHD), independent of apoE genotype and CRP (OR 1.32 [95 % CI 1.11; 1.58]). To conclude, in a general population prone to MetS, elevated apoE concentrations are strongly linked to HtgB and atherogenic dyslipidemia, irrespective of apoE genotype, are associated with MetS and CHD. Excess apoE reflects pro-inflammatory state and likely autoimmune activation.

Keywords

Apolipoprotein A-I Apolipoprotein B Apolipoprotein E concentrations Atherogenic dyslipidemia Coronary heart disease Hypertriglyceridemia with elevated apoB 

Abbreviation

apo

Apolipoprotein

LDL

Low-density lipoprotein

CHD

Coronary heart disease

Lp(a)

Lipoprotein(a)

CRP

C-reactive protein

MetS

Metabolic syndrome

HDL

High-density lipoprotein

SHBG

Sex hormone-binding globulin

HOMA

Homeostatic model assessment

TARF

Turkish adult risk factor study

HtgB

Hypertriglyceridemia with elevated apoB

VLDL

Very low-density lipoprotein

References

  1. 1.
    Mahley RW, Ji ZS (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 10:1–16Google Scholar
  2. 2.
    Dallongeville J, Lussier-Cacan S, Davignon S (1992) Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 33:447–454PubMedGoogle Scholar
  3. 3.
    Bennet AM, Di Angelantonio E, Ye Z et al (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298:1300–1311PubMedCrossRefGoogle Scholar
  4. 4.
    Dominczak MH, Caslake MJ (2011) Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 48:498–515CrossRefGoogle Scholar
  5. 5.
    Huang Y (2010) Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological disease. Curr Opin Lipidol 21:337–345PubMedCrossRefGoogle Scholar
  6. 6.
    Onat A, Hergenç G, Ayhan E et al (2007) Serum apolipoprotein E concentrations among Turks: additive information to genotype relative to dyslipidemia and metabolic syndrome. Arch Turk Soc Cardiol 35:449–457Google Scholar
  7. 7.
    Söderlund S, Watanabe H, Ehnholm C et al (2010) Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. Metabolism 59:1502–1509PubMedCrossRefGoogle Scholar
  8. 8.
    Mooijaart SP, Berbée JFP, van Heemst D et al (2006) ApoE plasma levels and risk of cardiovascular mortality in old age. PLoS Med 3:e176PubMedCrossRefGoogle Scholar
  9. 9.
    Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP (2012) Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease in women with high levels of HDL cholesterol and C-reactive protein. PLoS One 7:e39110PubMedCrossRefGoogle Scholar
  10. 10.
    Onat A, Can G, Ayhan E et al (2009) Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 58:1393–1399PubMedCrossRefGoogle Scholar
  11. 11.
    Onat A, Hergenç G (2011) Low-grade inflammation and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 60:499–512PubMedCrossRefGoogle Scholar
  12. 12.
    Onat A, Hergenç G, Bulur S et al (2010) The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 142:72–79PubMedCrossRefGoogle Scholar
  13. 13.
    Onat A, Kömürcü-Bayrak E, Can G et al (2010) Apolipoprotein A-I positively associated with diabetes in women independently of apoE genotype and apolipoprotein B levels. Nutrition 26:975–980PubMedCrossRefGoogle Scholar
  14. 14.
    Packard CJ, Ford I, Robertson M et al (2005) Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the prospective study of pravastatin in the elderly at risk. (PROSPER). Circulation 112:3058–3065PubMedCrossRefGoogle Scholar
  15. 15.
    Ray KK, Cannon CP, Cairns CP et al (2009) Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 29:424–430PubMedCrossRefGoogle Scholar
  16. 16.
    Onat A (2001) Risk factors and cardiovascular disease in Turkey. Atherosclerosis 156:1–10PubMedCrossRefGoogle Scholar
  17. 17.
    Grundy SM, Brewer HB, Cleeman JI et al (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438PubMedCrossRefGoogle Scholar
  18. 18.
    Onat A, Uyarel H, Hergenç G et al (2007) Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis 191:182–190PubMedCrossRefGoogle Scholar
  19. 19.
    Genuth S, Alberti KG, Bennett P et al (2003) Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. The expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:3160–3167PubMedCrossRefGoogle Scholar
  20. 20.
    Mather KJ, Hunt AE, Steinberg HO et al (2001) Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86:5457–5464PubMedCrossRefGoogle Scholar
  21. 21.
    Rose GA, Blackburn H, Gillum RF et al (1982) Cardiovascular survey methods, 2nd edn. WHO, Geneva, pp 124–127Google Scholar
  22. 22.
    Greenow K, Pearce NJ, Ramji DP (2005) The key role of apolipoprotein E in atherosclerosis. J Mol Med 83:329–342PubMedCrossRefGoogle Scholar
  23. 23.
    Onat A, Can G, Hergenç G et al (2007) Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 31:1119–1125CrossRefGoogle Scholar
  24. 24.
    Sniderman A, Scantlebury T, Cianflone K (2001) Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med 135:447–459PubMedGoogle Scholar
  25. 25.
    Janis MT, Metso J, Lankinen H et al (2005) Apolipoprotein activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 331:333–340PubMedCrossRefGoogle Scholar
  26. 26.
    Francis GA (2010) The complexity of HDL. Biochim Biophys Acta 1801:1286–9324bPubMedCrossRefGoogle Scholar
  27. 27.
    Vaisar T, Pennathur S, Green PS et al (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117:746–756PubMedCrossRefGoogle Scholar
  28. 28.
    Park KH, Shin DG, Kim JR et al (2010) The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med 25:129–136PubMedGoogle Scholar
  29. 29.
    Haase CL, Tybjaerg-Hansen A, Grande P et al (2010) Genetically elevated apolipoprotein A-I, high-density lipoprotein levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 95:E500–E510PubMedCrossRefGoogle Scholar
  30. 30.
    Barbagallo CM, Rizzo M, Noto D et al (2006) Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease. Metabolism 55:662–668PubMedCrossRefGoogle Scholar
  31. 31.
    Van den Elzen P, Garg S, Léon L et al (2005) Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437:906–910PubMedCrossRefGoogle Scholar
  32. 32.
    Ogasawara K, Mashiba S, Hashimoto H et al (2008) Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta 397:42–47PubMedCrossRefGoogle Scholar
  33. 33.
    Cigliano L, Pugliese CR, Spagnuolo MS et al (2009) Haptoglobin binds the antiatherogenic protein apolipoprotein E—impairment of apolipoprotein E stimulation of both lecithin: cholesterol acyltransferase activity and cholesterol uptake by hepatocytes. FEBS J 276:6158–6171PubMedCrossRefGoogle Scholar

Copyright information

© AOCS 2012

Authors and Affiliations

  • Altan Onat
    • 1
    • 2
  • Günay Can
    • 2
  • Ender Örnek
    • 3
  • Erkan Ayhan
    • 4
  • Nihan Erginel-Ünaltuna
    • 5
  • Sani N. Murat
    • 3
  1. 1.Turkish Society of CardiologyIstanbulTurkey
  2. 2.Cerrahpaşa Medical FacultyIstanbul UniversityIstanbulTurkey
  3. 3.Etlik Ihtisas Education HospitalAnkaraTurkey
  4. 4.Cardiology Department, Medical FacultyBalıkesir UniversityBalıkesirTurkey
  5. 5.Department of Genetics, Institute for Experimental MedicalIstanbul UniversityIstanbulTurkey

Personalised recommendations